ABAMETAPIR
| Brand name | XEGLYZE |
|---|---|
| Active ingredient | ABAMETAPIR |
| Strength | 0.74% |
| Dosage form | LOTION |
| Route | TOPICAL |
| Modality | Small molecule |
| FDA approval | July 2020 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 10292389 | December 2034 | product |
| 7812163 | October 2026 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.